Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment

Panchaprateep, Ratchathorn; Lueangarun, Suparuj

doi:10.1007/s13555-020-00448-x

Cited by 56 publications

(62 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O uso do Minoxidil oral em longo prazo tem demonstrado ser capaz de aumentar a densidade total do cabelo, apesar de trazer alguns efeitos adversos, tais como prurido no couro cabeludo, edema de membros inferiores, hipertricose facial e aumento da frequência cardíaca, porém sem alteração na pressão arterial. Todos esses efeitos foram bem tolerados e não foi preciso a cessação do tratamento (Gargallo, Gutierrez, Vanaclocha & Guerra-Tapia, 2015;Cranwell & Sinclair, 2016;Rossi et al, 2016;Panchaprateep & Lueangarun 2020;Ramos, Sinclair, Kasprzak, & Miot 2020).…”

Section: Discussionunclassified

“…O tratamento com Minoxidil oral aumenta significativamente o crescimento capilar, a densidade, o diâmetro do cabelo e diminui o ritmo de queda de cabelo. Baixa dose oral desse medicamento pode ser considerada uma modalidade terapêutica segura para os pacientes saudáveis, com poucos efeitos adversos sendo relatados, tais como hipertricose e edema de membros inferiores (Panchaprateep & Lueangarun, 2020).…”

Section: Discussionunclassified

“…Ocorre assim o encurtamento da fase telógena com aceleração dessa fase, levando a uma sincronização do ciclo capilar e um aumento da queda de cabelo no início da terapia com Minoxidil. Perda essa que é apenas temporária, pois o fio está apenas retornando para uma fase anágena que durará mais tempo (Panchaprateep & Lueangarun, 2020).…”

Section: Discussionunclassified

“…Doença cardíaca isquêmica, pericardite, derrame pericárdico e tamponamento pulmonar, hipertensão e insuficiência cardíaca de alto débito foram as condições mais observadas. A angina pode piorar ou surgir pela primeira vez durante o tratamento com Minoxidil, provavelmente sendo justificado devido ao aumento da demanda de oxigênio associado com o aumento da frequência cardíaca (Panchaprateep & Lueangarun, 2020).…”

Section: Discussionunclassified

“…Devido a essas condições e como medidas de segurança, o tratamento com Minoxidil oral deve ser desencorajado e desaconselhado em pacientes com fatores de risco cardiovascular, tais como indivíduos idosos com risco aumentado de infarto agudo do miocárdio, insuficiência cardíaca, doença renal crônica ou hipertensão grave. Essa modalidade terapêutica deve ser considerada apenas para indivíduos saudáveis (Panchaprateep & Lueangarun, 2020).…”

Section: Discussionunclassified

See 4 more Smart Citations

Alopecia androgenética: O uso do minoxidil e seus efeitos adversos

Gomes

Filho

2021

RSD

View full text Add to dashboard Cite

Objetivo: analisar os efeitos adversos do uso do Minoxidil em pacientes com Alopecia androgenética. Métodos: Foi efetuada uma revisão integrativa da literatura, método que possibilita uma síntese do conhecimento obtido em determinado número de estudos e sua incorporação em forma de aplicabilidade dos resultados obtidos de estudos significativos na prática da pesquisa baseada em evidências. Utilizou-se a questão de pesquisa “Quais são os efeitos adversos do uso de Minoxidil na Alopecia androgenética?”. Em seguida foi realizada uma pesquisa no banco de dados internacional Medical Publisher (PUBMED) e na Biblioteca Virtual em Saúde (BVS) com as palavras-chave “Minoxidil” AND “Alopecia” AND “Adverse effects”. Resultados: os efeitos adversos mais comuns com o uso do Minoxidil tópico são Hipertricose, prurido no couro cabeludo, dermatite de contato e eritema. Pele seca, aumento da sensibilidade, da produção de caspa também foram relatados. Alguns sintomas menos frequentes foram sinais cardiovasculares sistêmicos, como hipotensão e síncope. Conclusão: O tratamento com Minoxidil tanto em sua conformação tópica quanto sistêmica para a Alopecia Androgenética mostra-se uma medida efetiva e segura para o crescimento capilar, com efeitos adversos podendo ser bem controlados e tolerados.

show abstract

Section: Discussionunclassified

See 3 more Smart Citations

Alopecia androgenética: O uso do minoxidil e seus efeitos adversos

Gomes

Filho

2021

RSD

View full text Add to dashboard Cite

show abstract

Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEThere are knowledge gaps regarding the relative efficacy of 3 commonly used drugs for androgenetic alopecia (AGA), namely, minoxidil and the two 5-α reductase inhibitors dutasteride and finasteride.OBJECTIVE To examine the relative efficacy of any dose and administration route of minoxidil, dutasteride, and finasteride for the treatment of male AGA. DATA SOURCES Systematic searches were performed in PubMed on March 5, 2021, without date restrictions.STUDY SELECTION Eligible studies included those that investigated monotherapy with any dose and administration route of minoxidil, dutasteride, and finasteride.DATA EXTRACTION AND SYNTHESIS Data on the mean (SD) difference and sample size were used for the bayesian network meta-analyses. League tables and surface under the cumulative ranking curve values were used to examine the relative efficacy of the interventions. MAIN OUTCOMES AND MEASURESStudy end points were change in total and terminal hair count after 24 and 48 weeks of therapy. The 4 end points were quantified in hairs per square centimeters. RESULTSThe PubMed search yielded 848 records; after the 2 stages of screening, 23 studies were eligible for quantitative analyses. Mean (SD) age of patients ranged from 22.8 (3.3) years to 41.8 (12.3) years. The greatest increase in total hair count at 24 weeks (ie, first end point) was with 0.5 mg/d of dutasteride, which was significantly more efficacious than 1 mg/d of finasteride (mean difference, 7.1 hairs/cm 2 ; 95% CI, 5.1-9.3 hairs/cm 2 ) and minoxidil (0.25 mg/d [mean difference, 23.7 hairs/cm 2 ; 95% CI, 9.5-38.0 hairs/cm 2 ], 5 mg/d [mean difference, 15.0 hairs/cm 2 ; 95% CI, 3.9-26.1 hairs/cm 2 ], and 2% solution [mean difference, 8.5 hairs/cm 2 ; 95% CI, 4.8-12.3 hairs/cm 2 ]). The greatest increase in terminal hair count at 24 weeks (ie, second end point) was with 5 mg/d of minoxidil, which was significantly more efficacious than the 0.25-mg/d dose (mean difference, 43.6 hairs/cm 2 ; 95% CI, 29.7-57.7 hairs/cm 2 ) and its topical forms (in 2% [mean difference, 29.3 hairs/cm 2 ; 95% CI, 21.1-37.5 hairs/cm 2 ] and 5% [mean difference, 29.8 hairs/cm 2 ; 95% CI, 19.7-39.8 hairs/cm 2 ]); 5 mg/d of minoxidil was significantly more efficacious than 1 mg/d of finasteride (mean difference, 10.4 hairs/cm 2 ; 95% CI, 2.2-18.6 hairs/cm 2 ). The greatest increase in total hair count at 48 weeks (ie, third end point) was with 5 mg/d of finasteride, which was significantly more efficacious than 2% topical minoxidil (mean difference, 20.7 hairs/cm 2 ; 95% CI, 9.5-31.9 hairs/cm 2 ). The greatest increase in terminal hair count at 48 weeks (ie, fourth end point) was with 1 mg/d of finasteride, which was significantly more effective than topical minoxidil (in 2% [mean difference, 32.1 hairs/cm 2 ; 95% CI, 23.9-40.3 hairs/cm 2 ] and 5% [mean difference, 26.2 hairs/cm 2 ; 95% CI, 16.2-36.2 hairs/cm 2 ]). CONCLUSIONS AND RELEVANCEAs efficacy data from head-to-head trials accumulate, there could be a better sense of the relative efficacy of the different doses of the 5-...

show abstract

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia

Penha,

Miot,

Kasprzak

et al. 2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceThere has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment. However, the efficacy of oral minoxidil for male AGA is yet to be evaluated in comparative therapeutic trials.ObjectiveTo compare the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, vs twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male AGA.Design, Setting, and ParticipantsThis double-blind, placebo-controlled randomized clinical trial was conducted at a single specialized clinic in Brazil. Eligible men with AGA aged 18 to 55 years classified using the Norwood-Hamilton scale as 3V, 4V, or 5V were included and randomized. Data were collected from January to December 2021, and data were analyzed from September 2022 to February 2023.InterventionsParticipants were randomized 1:1 into 2 groups: oral minoxidil, 5 mg, daily and topical placebo solution; or 1 mL of topical minoxidil, 5%, twice daily and oral placebo for 24 weeks.Main Outcomes and MeasuresThe primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp. The secondary outcomes were change in total hair density and photographic evaluation.ResultsAmong 90 enrolled participants, 68 completed the study; of these, the mean (SD) age was 36.6 (7.8) years. A total of 33 participants were enrolled in the oral minoxidil group and 35 in the topical treatment group. Both groups were homogenous in terms of demographic data and AGA severity. For the frontal area, the mean change from baseline to week 24 between groups was 3.1 hairs per cm2 (95% CI, −18.2 to 21.5; P = .27) for terminal hair density and 2.6 hairs per cm2 (95% CI, −10.3 to 15.8; P = .32) for total hair density. For the vertex area, the mean change from baseline to week 24 was 23.4 hairs per cm2 (95% CI, −0.3 to 43.0; P = .09) for terminal density and 5.5 hairs per cm2 (95% CI, −12.5 to 23.5; P = .32) for total hair density. According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, −12 to 36; P = .24). The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).Conclusions and RelevanceIn this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.Trial RegistrationBrazilian Registry of Clinical Trials Identifier: RBR-252w9r

show abstract

Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment

Cited by 56 publications

References 30 publications

Alopecia androgenética: O uso do minoxidil e seus efeitos adversos

Alopecia androgenética: O uso do minoxidil e seus efeitos adversos

Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia

Contact Info

Product

Resources

About